Pilot Study of Tocilizumab Monotherapy for Active Chronic Periaortitis

Peking Union Medical College Hospital12 enrolled

Overview

This is a prospective study to investigate the treatment response of Tocilizumab on patients with active chronic periaortitis (CP). Methods: patients with a definite or possible diagnosis of CP at acute active stage were enrolled for this study and accepted Tocilizumab monotherapy for 3 months. Endpoints: The primary endpoint is to investigate the treatment response of Tocilizumab; the secondary endpoints include the improvement of inflammatory markers, the frequency of adverse events.

Patients enrolled received intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months. Demographic and clinical features, laboratory findings and imaging examinations were recorded at baseline and during 3-month follow-up. Imaging improvement was converted into the ratio of perivascular soft tissues shrinkage by evaluating 2 dimensions of greatest change on computed tomography (CT) at baseline and after 3 months. Partial remission was defined as obtaining alleviation of symptoms and normalization of inflammatory markers including erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP), with shrinkage of soft tissue mass in imaging \<70%. Further, complete remission was defined as normalization of inflammatory markers accompanied by shrinkage of soft tissue mass ≥70%.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Periaortitis Tocilizumab Monotherapy

Interventions

Tocilizumab monotherapyDRUG

intravenous infusions of TCZ (8 mg/kg) at inclusion and then every 4 weeks for at least 3 months

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. adults ≥ 18 years of age at time of informed consent; 2. meet clinical diagnostic criteria including (1) imaging findings show perivascular soft tissue density mass surrounding thoracic aorta, abdominal aorta or iliac arteries; (2) histopathological findings show fibrous tissue with chronic inflammatory infiltrate comprised of lymphocytes, plasma cells and macrophages (Neutrophils and granulomas are rare). Patients who satisfied (1) but without histopathological examination were perceived as possible CP; 3. at active stage: clinical symptoms or organ involvement; a higher level of ESR and CRP than normal; Exclusion Criteria: 1. Secondary forms of CP related to drugs, infections, malignancies, Erdheim-Chester disease or other autoimmune diseases were excluded. 2. Combined with other autoimmune diseases. 3. Known immunodeficiency disorder. 4. Pregnancy, lactation, or planning to become pregnant within 6 months of the test. 5. Positive test for, or prior treatment for, hepatitis B or HIV infection. A positive test for hepatitis B is detection of hepatitis B surface antigen (HBsAg) or HBV-DNA. 6. Evidence of active tuberculosis (TB), including Chest X-ray and PPD. 7. Severe abnormal liver function or cardiac insufficiency. 8. Any reason the investigator think that should not attend this trial.

Locations (1)

Yunyun Fei

Beijing, China

Outcomes

Primary Outcomes

treatment response

the rate of partial remission and complete remission after 3-month TCZ monotherapy

Time frame: three months

Secondary Outcomes

the frequency of treatment related adverse events

adverse events caused by TCZ during 3-month follow-up.

Time frame: three months

the improvement of inflammatory markers

including erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (hsCRP).

Time frame: three months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.